Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma

  1. Rodriguez-Otero, P.
  2. Ayers, D.
  3. Cope, S.
  4. Davies, F.E.
  5. Delforge, M.
  6. Mojebi, A.
  7. Jansen, J.P.
  8. Weisel, K.
  9. Hege, K.
  10. Dhanasiri, S.
Aldizkaria:
Leukemia and Lymphoma

ISSN: 1029-2403,  1042-8194

Argitalpen urtea: 2021

Alea: 62

Zenbakia: 10

Orrialdeak: 2482-2491

Mota: Artikulua

DOI: 10.1080/10428194.2021.1913143 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus